Comparative analysis of cardiogenic shock outcomes in acute myocardial infarction with polyvascular disease

Marlon V Gatuz1, Rami Abu-Fanne1, Dmitry Abramov2

  • 1Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Insights

Polyvascular disease significantly worsens outcomes for patients with acute myocardial infarction (AMI)-induced cardiogenic shock (CS). Increased diseased vascular beds correlate with higher mortality and adverse events, necessitating targeted management strategies.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) is a primary cause of mortality in acute myocardial infarction (AMI) patients.
  • Patients with co-existing vascular disease face particularly high mortality risks.
  • The impact of polyvascular disease extent on AMI-induced CS outcomes requires further investigation.

Purpose of the Study:

  • To assess the association between the extent of polyvascular disease and in-hospital management and outcomes in patients with AMI-induced CS.
  • To stratify patients based on the number of diseased vascular beds and STEMI/NSTEMI status.
  • To evaluate the relationship between polyvascular disease burden and major adverse cardiovascular and cerebrovascular events (MACCE).

Main Methods:

  • Utilized the National Inpatient Sample (NIS) database from 2016-2019.
  • Identified adult patients with AMI and CS with known vascular disease.
  • Stratified patients by the number of diseased vascular beds and analyzed STEMI/NSTEMI subgroups.

Main Results:

  • A total of 136,245 patients were analyzed; 57.9% had STEMI and 42.1% had NSTEMI.
  • The likelihood of undergoing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) decreased with an increasing number of diseased vascular beds.
  • A direct dose-response relationship was observed between the number of diseased vascular beds and adverse outcomes, including MACCE, mortality, and acute CVA.

Conclusions:

  • Polyvascular disease significantly exacerbates outcomes in patients with AMI-induced CS.
  • Early identification and aggressive management of polyvascular disease are crucial for this high-risk population.
  • Further research is needed to develop targeted treatment strategies for patients with polyvascular disease and AMI-induced CS.
Abstract